Jamiruddin, Dr. Mohd. RaeedMirza, Maisa Tasnim2023-04-132023-04-1320222022-08ID: 18146017http://hdl.handle.net/10361/18147Cataloged from PDF version of thesis.Includes bibliographical references (pages 22-25).This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2022.The most common cause of cancer among women is breast cancer, accounting for almost one in every ten new cases of cancer every year. Invasive lesions include ductal carcinoma (now called 'no special type' (NST)) as well as lobular carcinoma, both of which have preinvasive counterparts in the form of ductal carcinoma in situ along with lobular cancer in situ (or lobular neoplasia). DCIS normally has no outward signs or symptoms. Yet, a lump or discharge from the nipple might be observed in a few cases. Many classification systems have been created due to the microscopic heterogeneity of DCIS. This review was conducted to find out whether Tamoxifen is the ideal choice of therapy for post operative DCIS among other therapies.25 pagesenBrac University theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission.Aromatase inhibitorsBreast cancerDuctal carcinoma in situEstrogen receptor positiveHormonal therapyTamoxifen.Tamoxifen.Breast--Cancer--Chemoprevention.Thesis